ArticleClinical, cosmetic and investigational dermatology2026
Molecular Evidence for
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pachyonychia congenita tarda (PCT) is a rare late-onset variant of pachyonychia congenita (PC), with its nosological status remaining controversial due to limited molecular confirmation in adult-onset cases. We report a 57-year-old Chinese woman who presented with a four-year history of progressive, painful thickening of all 20 nails, accompanied by mild palmoplantar keratoderma. Repeated mycological examinations were negative, and no clinical improvement was observed after prolonged antifungal therapy. Familial segregation analysis could not be performed because biological samples from relatives were unavailable, and the patient reported no known affected relatives. Whole-exome sequencing (WES), followed by Sanger confirmation, identified a heterozygous missense variant in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.